Sequenom Posts 28 Percent Increase in Q4 Revenues as SEC Wraps up Investigation
March 09, 2011
Sequenom Posts 28 Percent Increase in Q4 Revenues as SEC Wraps up Investigation
The company's CEO said that SEC staff has told the firm that the agency may bring civil injunction action against Sequenom, "alleging that we violated certain anti-fraud and books of record" infractions.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Sequenom's Q4 Revenues More than Double; Shares Fall in Early Trade
March 8, 2013 / GenomeWeb Daily News - Sequenom's Q1 Revenues Rise as Firm Details Plan for T21 Test
May 7, 2010 / GenomeWeb Daily News - Sequenom's Q4 Revenues Drop 11 Percent
March 16, 2010 / GenomeWeb Daily News - MaterniT21 Doubles Sequenom's Revenues; Firm Inks Deal with Blue Cross Blue Shield Association
May 15, 2013 / Clinical Sequencing News - Credit Suisse Upgrades Sequenom to Neutral
May 13, 2013 / GenomeWeb Daily News